Most Read Articles
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.

Product Highlight - BLACKMORES ESSENTIAL LIVO

01 Oct 2015
BLACKMORES ESSENTIAL LIVO – Phosphatidylcholine, Zinc and Chromium Capsules
  • The support of normal cholesterol, fat metabolism and liver health
  • Improved digestive assistance via the support of fat, carbohydrate and protein metabolism
  • Liver detoxification and antioxidant support
  • Maintenance of normal glucose metabolism
References:
1. Canty D and Zeisel S, Lecithin and Choline in Human Health and Disease, Nutrition Reviews, 1994; 52 (10): 327-339
2.
Health Canada. Choline: Monograph, .September, 2009. http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=195&lang=eng (accessed 18th January 2012)
3. Hendler SS. PDR for nutritional supplements 2nd edition. Montvale, Physicians desk reference, 2008
4.
NHMRC, Chromium, Nutrient Reference Values for Australia and New Zealand, Commonwealth of Australia 2006; 235-240
5.
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=64&lang=eng Health Canada Monograph (accessed 23/10/12)

Further information is available in Section 1g and 31b, New In This Issue and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.